Navigation Links
Cardiogenesis Reports Third Quarter 2008 Results
Date:11/13/2008

in this news release related to the possible effectiveness of the Company's technologies and the effect of such technologies on the Company's sales, profitability, the adoption of its technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; the effects of recent disruptions in global credit and equity markets and other adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 and the Company's other recent SEC filings. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

CARDIOGENESIS CORPORATION

CONDENSED CO
'/>"/>

SOURCE Cardiogenesis Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results
2. Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. China Biologic Products Reports Strong Third Quarter 2008 Results
6. Imagenetix, Inc. Reports Second Quarter and Six Month Results
7. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
8. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
9. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
10. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
11. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014 Naurex Inc., a ... drugs for diseases of the central nervous system, today ... chief executive officer, will present at the 33 rd ... will take place at 3:00 p.m. PST on Tuesday, ... San Francisco, Calif. ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources ... will grow at a 12 percent compound annual growth ... of the aging population and the increasing adoption of ... America will also spur demand for dental ... dental implant and periodontal treatments. Other key ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 Today, ... locate its pilot production facility and future company ... and produce innovative new materials that safely and ... not only because of its historic, strong support ... efforts to attract leading edge, technology-based companies such ...
(Date:12/19/2014)... Reports from CDC show approximately ... one or more chronic health conditions - including cardiovascular ... some of these diseases, but may not eliminate the ... While implanted nerve stimulation devices today offer relief, they ... can induce side effects. , To eliminate the ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
... Calif., June 3 Ingenuity Systems, the,leading provider ... signing of a four year agreement with Boehringer ... used throughout the,Boehringer Ingelheim research and development organization ... a general tool for biological search,and exploration., ...
... N.C. -- Microscopic robots crafted to maneuver separately without ... after years of continuing research led by a Duke ... to do assembly and control at this fine a ... Donald, a Duke professor of computer science and biochemistry. ...
... 2 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) ... data,for its FDA-approved diabetes drugs, BYETTA(R) (exenatide) injection ... and,obesity drug candidates at the American Diabetes Association,s ... Francisco, CA from June 6 to,10. The company ...
Cached Biology Technology:Ingenuity Systems Announces Multi-Year Agreement With Boehringer Ingelheim 2Microrobots dance on something smaller than a pin's head 2Microrobots dance on something smaller than a pin's head 3Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 2Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 3Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 4Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 5Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 6Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 7
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... for killer diseases such as HIV/AIDS, TB, Malaria, Chagas ... is despite the fact that these diseases mainly affect ... is inhibitive due to lack of economic demand. Researchers ... of some vaccines and diagnostics) would increase if more ...
... hand-in-hand with enlargement of a brain region that handles negative ... Texas Veterans Health Care System have found. , ... and contains more nerve cells in humans who carry the ... regions that receive input from the pulvinar are more strongly ...
... have limited lifespans, which means that they must be ... into the blood cell types needed by the body. ... Molecular Biology Laboratory (EMBL) unit in Monterotondo, Italy, in ... the University of Lund in Sweden, have now uncovered ...
Cached Biology News:Increase in drug development for killer diseases is not enough 2Gene linked with mental illness shapes brain region, researchers find 2Lost in the labyrinth 2
... SpeedVac™ Concentrators set the standard for sample concentration ... with large chamber uses a combination of centrifugal ... in a single run. , SC210A comes equipped ... for long lasting chemical compatibility ...
Digital display of time, vacuum and temperature , Dual vacuum control of ramping rate and ultimate level , Comes complete with RH40-12 (40 x 1.5 ml) Rotor and (2) Glass Condensation Flasks. ...
... series of vacuum concentrators/centrifugal evaporators offers a ... to rapid and safe concentration of heat-labile ... with oil-free or high vacuum pumps, a ... selection of rotors (eliminating sample loss by ...
... George Paxinos Affiliation: School of Psychology, The University ... Affiliation: Curtin University of Technology, Perth, Australia This ... of the rat brain. It is a ... revison and extension of the compact 3rd edition. ...
Biology Products: